Welcome to our dedicated page for Instil Bio SEC filings (Ticker: TIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotech filings can overwhelm even seasoned analysts. Instil Bio’s SEC documents mix dense immuno-oncology science with detailed cash-runway math, facility build-outs, and CoStAR trial milestones—information scattered across 10-K risk factors, 10-Q footnotes, and sudden 8-K updates. Finding the right paragraph before the next financing decision shouldn’t take all night.
Stock Titan’s AI steps in as your research partner. Our algorithms parse every Instil Bio annual report 10-K simplified for you, flagging R&D spending trends and FDA feedback. Receive alerts the moment an Instil Bio 8-K material events explained lands on EDGAR, and scroll through Instil Bio insider trading Form 4 transactions in real-time—no more manual form hunting. Prefer narrative guidance? Select “understanding Instil Bio SEC documents with AI” to see plain-English summaries that answer common queries like “What changed in the latest Instil Bio quarterly earnings report 10-Q filing?” or “Which executives exercised options this week?”
All filing types are covered and continuously updated:
- Instil Bio executive stock transactions Form 4 with instant filters
- Instil Bio proxy statement executive compensation highlights
- Instil Bio earnings report filing analysis that links revenue to trial progress
Use these insights to monitor burn rate before a capital raise, compare trial timelines across years, or track partnership disclosures. With AI-powered summaries, expert commentary, and searchable full text, Instil Bio SEC filings explained simply become actionable intelligence you can trust.
Instil Bio, Inc. reported a net loss of $21.4 million for the quarter and $49.6 million for the six months ended June 30, 2025, driven by increased R&D activity and restructuring and impairment charges of $16.6 million related to listing the Tarzana facility for sale. The company recognized a $10.0 million in-process R&D charge tied to a development milestone under its ImmuneOnco collaboration after IND clearance for AXN-2510/IMM2510 in the U.S.
The balance sheet shows $103.6 million of cash, cash equivalents, restricted cash, marketable securities and long-term investments and assets held for sale of $112.1 million (Tarzana). Debt includes a $85.6 million term loan (interest-only at 6.35%, two-year term). Management states current resources are expected to fund operations beyond 2026, and the company completed an ATM sale for $6.6 million in Q2.
Instil Bio, Inc. furnished an 8-K reporting a corporate update and its financial results for the quarter ended June 30, 2025. The company said the details appear in a press release filed as Exhibit 99.1 to the 8-K and that the information is being furnished (not "filed") under the Securities Exchange Act. No financial figures, operational details, or other substantive results are included in the 8-K text itself; readers are directed to the attached press release for the actual results.
Vivo Capital IX, LLC and Vivo Capital Fund IX, L.P. reported beneficial ownership of 292,743 shares of Instil Bio, Inc. common stock, equal to 4.5% of the company based on 6,559,927 shares outstanding as disclosed May 9, 2025. The shares are held of record by Vivo Capital Fund IX, L.P., and Vivo Capital IX, LLC is the fund's general partner.
The Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, shows the reporting persons have sole voting and dispositive power over the 292,743 shares and includes a certification that the position was not acquired to change or influence control. The filing is signed by Frank Kung on 08/12/2025.
FAQ
What is the current stock price of Instil Bio (TIL)?
What is the market cap of Instil Bio (TIL)?
